Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Generic Biologics Short-Term Plan Includes Immunogenicity Document

Executive Summary

Immunogenicity and chemistry of follow-on biologics will be among the first issues FDA tackles in documents issued on the topic, Acting Commissioner Lester Crawford said at the Generic Pharmaceutical Association's annual meeting in Boca Raton, Fla

You may also be interested in...



FDA Sees Critical Path Opportunity To Address Follow-On Biologics

FDA's Critical Path opportunities list suggests that the agency is actively working to lay the scientific groundwork for follow-on biologics

FDA Sees Critical Path Opportunity To Address Follow-On Biologics

FDA's Critical Path opportunities list suggests that the agency is actively working to lay the scientific groundwork for follow-on biologics

Follow-Ons Off? FDA Shelves Near-Term Plans For Biologics Documents

FDA's decision not to release follow-on biologics documents in the near future suggests proponents of such products may turn their focus to Congress or the courts in an effort to establish a clear regulatory framework

Related Content

Topics

UsernamePublicRestriction

Register

PS045468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel